Related Experiment Video
Updated: Apr 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Device-detected atrial fibrillation: what to do with asymptomatic patients?
Carol Chen-Scarabelli1, Tiziano M Scarabelli2, Kenneth A Ellenbogen3
1Veterans Affairs Ann Arbor Health Care System, University of Michigan, Ann Arbor, Michigan.
Insights
Subclinical atrial tachyarrhythmias (ATs) detected by devices increase stroke risk. Guidelines recommend stroke risk assessment and anticoagulation for nonvalvular atrial fibrillation (AF) to prevent thromboembolic events.
Area of Science:
- Cardiology
- Electrophysiology
- Neurology
Background:
- Atrial fibrillation (AF) is a prevalent arrhythmia associated with significant stroke risk.
- Subclinical atrial tachyarrhythmias (ATs) detected by cardiac implantable electronic devices (CIEDs) are linked to thromboembolic events.
- Clinical management of device-detected AT often involves delayed treatment or continued surveillance.
Purpose of the Study:
- To review the epidemiology of atrial fibrillation.
- To discuss the mechanisms of stroke in patients with AF.
- To examine the clinical implications of device-detected AF and its association with stroke risk.
Main Methods:
- Literature review of epidemiological data on AF.
- Analysis of mechanisms linking AF to thromboembolic events.
- Discussion of current clinical practice guidelines and device-detected AF management.
Main Results:
- AF increases stroke risk irrespective of symptoms.
- Device-detected ATs are associated with a higher risk of thromboembolic events.
- Current guidelines recommend stroke risk stratification using CHA2DS2-VASc score for nonvalvular AF.
Conclusions:
- Oral anticoagulation is recommended for nonvalvular AF with CHA2DS2-VASc score ≥2.
- Device-detected AF warrants careful consideration for stroke prevention strategies.
- Further research and updated clinical approaches are needed for managing device-detected ATs.
Abstract:
Atrial fibrillation (AF) is the most common clinically significant arrhythmia and conveys an increased risk of stroke, regardless of whether it is symptomatic. Despite multiple studies supporting an association between subclinical atrial tachyarrhythmias (ATs) detected by cardiac implantable electronic devices and increased risk of thromboembolic events, clinical intervention for device-detected AT remains sluggish, with some clinicians delaying treatment and instead opting for continued surveillance for additional or longer episodes. However, the 2014 updated clinical practice guidelines on AF recommend use of the CHA2DS2-VASc stroke risk score for nonvalvular AF, with oral anticoagulation recommended for scores ≥2, regardless of whether AF is paroxysmal, persistent, or permanent. This paper reviews the epidemiology of AF and mechanisms of stroke in AF, and discusses device-detected AF and its clinical implications.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Atherosclerosis III: Management
Mitral Stenosis III: Medical Management
Dysrhythmias V: Evaluating Dysrhythmias

